AiRuiKa (camrelizumab) / CG Invites, Jiangsu Hengrui Pharma, HLB Bio Group, NPO Petrovax - LARVOL DELTA

Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study. (PubMed, Front Immunol) - "Tislelizumab exhibited the highest incidence at 3.48%, followed by camrelizumab at 3.10%, sintilimab at 2.24%, and toripalimab at 1.75%. Furthermore, higher baseline TSH levels, younger age, and treatment with tislelizumab or camrelizumab were associated with an increased risk of immune-related hypothyroidism, whereas lower baseline TSH levels were linked to a higher risk of immune-related hyperthyroidism. Close clinical and hormonal monitoring is recommended for patients with high-risk factors before and throughout the course of immunotherapy, particularly during the initial 2 to 4 months of PD-1 inhibitor treatment."

Adverse events • Journal • Endocrine Disorders • Oncology

Resilire: Reverse HER2-negative Immune Resistant Breast Cancer (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: Fudan University | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Jul 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor

Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma. (PubMed, Br J Cancer) - P2 | "We established a model that could predict the prognosis of combined therapy. The model could predict outcomes and reflect the systemic immune and inflammatory status, which is beneficial for risk stratification and therapeutic modification."

Biomarker • IO biomarker • Journal • P2 data • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • CD8

Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB NSCLC. (PubMed, Ann Nucl Med) - P2 | "Pre-NAT SUVmax, and ΔSUVmax% are promising biomarkers for predicting pathological response to neoadjuvant camrelizumab and chemotherapy."

Journal • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology

Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial. (PubMed, BMC Med) - P2 | "Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with oral sorafenib shows manageable safety profile but modest antitumor activity in patients with BCLC stage C advanced HCC."

Journal • P2 data • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients. (PubMed, BMC Cancer) - "CAM combined with apatinib plus IRT as a second-line treatment exhibits acceptable efficacy and safety in advanced or metastatic ESCC patients. The model that combines clinical and radiomic features has the greatest ability to predict the survival of advanced or metastatic ESCC patients."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Fatigue • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Squamous Cell Carcinoma • Thrombocytopenia

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study. (PubMed, BMC Med) - P1/2 | "Our data support the potential efficacy of neoadjuvant SCRT followed by camrelizumab and CAPOX regimen in LARC, as indicated by 3-year survival outcomes, suggesting that this may be an alternative therapeutic strategy, especially with the potential to address an unmet need for MSS patients."

Journal • P2 data • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor • PD-L1

NEOADJUVANT CHEMO-RADIOTHERAPY WITH OR WITHOUT PD-1/PD-L1 INHIBITORS IN LOCALLY ADVANCED RECTAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS (DDW 2025) - "SRCT with PD-1/PD-L1 inhibitors shows better pathological response rates than LRCT. Among the inhibitors, Camrelizumab and Tislelizumab are particularly effective, while Sintilimab and Pembrolizumab show less significant results."

Metastases • Retrospective data • Review • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial. (PubMed, BMC Cancer) - P2 | "The combination of HAIC, camrelizumab, and apatinib as conversion therapy shows promising clinical benefits and a manageable safety profile in patients with uHCC. Future randomized controlled trials are warranted."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC (clinicaltrials.gov) - P=N/A | N=97 | Active, not recruiting | Sponsor: First Hospital of China Medical University

Checkpoint inhibition • Combination therapy • Metastases • New trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

TAE-HAIC combined with lenvatinib plus camrelizumab or sintilimab plus bevacizumab for unresectable HCC with high tumor burden: a retrospective comparison (ESMO-GI 2025) - No abstract available

Retrospective data • Hepatocellular Cancer • Oncology

Neoadjuvant therapy with mFOLFOXIRI combined with camrelizumab and bevacizumab for microsatellite stable, locally advanced rectal cancer: A single-arm, open-label phase II study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: ChiCTR2100054182 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (ESMO.org) - "First-line treatment: For patients with well-preserved liver function and ECOG PS 0-1 (BCLC B-C): Atezolizumab–bevacizumab [I, A; ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.1 score: 5] or durvalumab–tremelimumab [I, A; ESMO-MCBS v1.1 score: 5] are recommended; In patients with portal hypertension, screening for varices is strongly recommended before initiation of atezolizumab–bevacizumab; Camrelizumab–rivoceranib [I, B; not EMA or FDA approved] or nivolumab–ipilimumab [I, B; EMA approved, not FDA approved] can be recommended...Second-line treatment: For patients with well-preserved liver function and ECOG PS 0-1 who have progressed on one or more systemic therapies: Regorafenib [I, A; ESMO-MCBS v1.1 score: 4; EMA and FDA approved after first-line sorafenib] or cabozantinib [I, A; ESMO-MCBS v1.1 score: 3; EMA and FDA approved after first-line sorafenib] should be considered..."

Clinical guideline • Hepatocellular Cancer

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma. (PubMed, Cancer Manag Res) - P2 | "The combination of programmed cell death-1 (PD-1) blockade camrelizumab plus apatinib (an antiangiogenic agent) and temozolomide has displayed promising therapeutic effects in patients with advanced acral melanoma (AM) in a non-randomized Phase II clinical trial (NCT04397770). Overall, 92.4% and 45.2% of the patients experienced any-grade and grade 3-4 TRAEs, respectively. This study provides real-world evidence that support the effectiveness and safety of combined anti-PD-1 antibody, apatinib and temozolomide for treating advanced AM, demonstrating a considerable ORR and prolonged survival, as well as acceptable tolerability."

Journal • Real-world evidence • Melanoma • Oncology • Solid Tumor

The Effect of Serum Ferritin in irAE (clinicaltrials.gov) - P=N/A | N=1500 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

Adverse events • IO biomarker • New trial • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

Camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): 1-year outcomes from the phase II trial. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05673577 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Metastases • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Camrelizumab plus low–dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T–cell lymphoma: a multicenter phase II study (ICML 2025) - No abstract available

Clinical • P2 data • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Updated network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: consistent role of TACE (EASL 2025) - " Transarterial chemoembolization (TACE) combined with lenvatinib provided the greatest improvement in OS compared to sorafenib, with a hazard ratio of 0.41 (95% confidence interval, 0.30–0.58), followed by sintilimab+IBI305 (0.57; 0.43–0.75), camrelizumab+rivoceranib (0.62; 0.48–0.80), atezolizumab+bevacizumab (0.66; 0.51– 0.85), lenvatinib+pembrolizumab (0.77; 0.62–0.97), and tremelimumab+durvalumab (0.78; 0.64–0.95). Our first-line analysis consistently scored TACE+lenvatinib best for survival outcomes, followed by various immunotherapy-based combinations in advanced HCC. This hierarchy was sustained in aggressive tumors or hepatitis B carriers."

Metastases • Retrospective data • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma: Analysis of the Phase Ib Part (ICML 2025) - No abstract available

Metastases • P1 data • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

CCGLC-001: Combined HAIC, TKI/anti-VEGF and ICIs As Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Ze-yang Ding, MD | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

Integrating quality of life and overall survival to quantify benefit from frontline systemic therapy options in unresectable/advanced hepatocellular carcinoma: a network meta-analysis (EASL 2025) - " Ten studies, enrolling 7,268 patients treated with Sorafenib, Lenvatinib, Nivolumab, Tislelizumab, Durvalumab, Atezolizumab+Bevacizumab, Sintilimab+IBI305, Durvalumab+Tremelimumab, Nivolumab+Ipilimumab, Atezolizumab+Cabozantinib, Lenvatinib+Pembrolizumab, Camrelizumab+Apatinib were included... Atezolizumab plus Bevacizumab was associated with the highest magnitude in reducing the risk of deterioration of most HR-QoL domains compared to other systemic therapies. Integrated assessment of OS with HR-QoL assessed by MDC suggests atezolizumab plus bevacizumab to provide the best balance between QoL preservation and OS benefit compared to other systemic therapy options in unresectable/advanced HCC."

HEOR • Metastases • Retrospective data • Fatigue • Hepatocellular Cancer • Hepatology • Oncology • Pain • Solid Tumor

ESMO Living Guideline: Hepatocellular Carcinoma, v1.0 April 2025 (ESMO.org)

Clinical guideline • Hepatocellular Cancer

Efficacy of sequential radiotherapy after the combination of transcatheter arterial chemoembolization with lenvatinib and anti-PD-1 antibodies for unresectable hepatocellular carcinoma (APASL 2025) - "All patients received lenvatinib (8 mg for body weight < 60 kg or 12 mg for body weight≥ 60 kg) orally once daily, and anti-PD-1 antibodies (sintilimab 200 mg, tislelizumab 200 mg, camrelizumab 200 mg, toripalimab 240 mg, or pembrolizumab 200 mg) intravenously once every 3 weeks. Sequential radiotherapy after triple therapy enhanced tumor response and survival benefits for uHCC patients, with manageable adverse effects. Table and Figure:Figure 1.Fig. 1."

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Hepatic artery infusion chemotherapy(HAIC) combined with Lenvatinib and Camrelizumab for hepatocellular carcinoma(HCC) with portal vein tumor thrombus(PVTT): a prospective longitudinal real-world study (EASL 2025) - P2 | "For patients with HCC complicated by PVTT, the combination of HAIC with camrelizumab and lenvatinib shows promising clinical efficacy, and the toxicity is acceptable."

Clinical • Real-world • Real-world evidence • Dermatology • Hematological Disorders • Hepatocellular Cancer • Hypertension • Oncology • Renal Disease • Solid Tumor • Thrombosis